Interferon Alpha 2a and 2b in Ophthalmology: A Review

Lewczuk, Natalia; Zdebik, Alexander; Bogusławska, Joanna

doi:10.1089/jir.2018.0125

Cited by 44 publications

(21 citation statements)

References 70 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Finally, ischemic events are reported, but in less than 1% of patients treated and the changes often regress while on the drug or if the treatment is stopped [97]. Another review of Lewczuk et al suggests a possible association between interferon alpha and retinopathy [98].…”

Section: Ocular Adverse Effects To Treatmentmentioning

confidence: 99%

Ocular Manifestations in Patients with Philadelphia-Negative Myeloproliferative Neoplasms

Liisborg

Hasselbalch

Sørensen

2020

Cancers

View full text Add to dashboard Cite

The major complications of Philadelphia-negative (Ph-Negative) myeloproliferative neoplasms (MPNs) are thrombosis, haemorrhage and leukemic transformation. As systemic and haematological diseases, MPNs have the potential to affect many tissues and organs. Some complications lead to the diagnosis of MPNs, but other signs and symptoms are often misdiagnosed or neglected as a sign of MPN disease. Therefore, we reviewed the current literature to investigate and delineate the clinical manifestations seen in the eyes of Ph-negative MPN patients. We found that ocular manifestations are common among patients with MPNs. The most frequently described manifestations are due to the consequences of haematological abnormalities causing microvascular disturbances and hyperviscosity. More serious and vision-threatening complications as thrombotic events in the eyes have been repeatedly reported as well. These ocular symptoms may precede more serious extraocular complications. Accordingly, combined ophthalmological and haematological management have the potential to discover these diseases earlier and prevent morbidity and mortality in these patients. Furthermore, routine ophthalmological screening of all newly diagnosed MPN patients may be a preventive approach for early diagnosis and timely treatment of the ocular manifestations.

show abstract

Section: Ocular Adverse Effects To Treatmentmentioning

confidence: 99%

Ocular Manifestations in Patients with Philadelphia-Negative Myeloproliferative Neoplasms

Liisborg

Hasselbalch

Sørensen

2020

Cancers

View full text Add to dashboard Cite

show abstract

“…Recombinant type I interferons (IFNα and IFNβ), have been approved for the treatment of a number of malignancies, viral infections and multiple sclerosis [46]. In addition, IFNα has been used in Europe to treat various forms of uveitis [27,47]. However, their use in the clinic is associated with severe toxicity, including lymphopenia, depression and weight loss.…”

Section: Discussionmentioning

confidence: 99%

“…This has been exploited to develop treatments for multiple sclerosis [24], psoriasis [25], and coeliac diseases [26]. Several studies have reported the success of use of IFNα in a number of ocular disorders, including uveitis [27][28][29]. Type I interferon (IFNα or IFNβ) are commonly used to treat relapsing multiple sclerosis (MS) [24].…”

Section: Introductionmentioning

confidence: 99%

A C-terminal peptide from type I interferon protects the retina in a mouse model of autoimmune uveitis

et al. 2020

View full text Add to dashboard Cite

Experimental autoimmune uveitis (EAU) in rodents recapitulates many features of the disease in humans and has served as a useful tool for the development of therapeutics. A peptide from C-terminus of interferon α1, conjugated to palmitoyl-lysine for cell penetration, denoted as IFNα-C, was tested for its anti-inflammatory properties in ARPE-19 cells, followed by testing in a mouse model of EAU. Treatment with IFNα-C and evaluation by RT-qPCR showed the induction of anti-inflammatory cytokines and chemokine. Inflammatory markers induced by treatment with TNFα were suppressed when IFNα-C was simultaneously present. TNF-α mediated induction of NF-κB and signaling by IL-17A were attenuated by IFNα-C. Differentiated ARPE-19 cells were treated with TNFα in the presence or absence IFNα-C and analyzed by immmunhistochemistry. IFNα-C protected against the disruption integrity of tight junction proteins. Similarly, loss of transepithelial resistance caused by TNFα was prevented by IFNα-C. B10.RIII mice were immunized with a peptide from interphotoreceptor binding protein (IRBP) and treated by gavage with IFNα-C. Development of uveitis was monitored by histology, fundoscopy, SD-OCT, and ERG. Treatment with IFNα-C prevented uveitis in mice immunized with the IRBP peptide. Splenocytes isolated from mice with ongoing EAU exhibited antigen-specific T cell proliferation that was inhibited in the presence of IFNα-C. IFNα-C peptide exhibits anti-inflammatory properties and protects mice against damage to retinal structure and function suggesting that it has therapeutic potential for the treatment of autoimmune uveitis. Citation: Ahmed CM, Ildefonso CJ, Johnson HM, Lewin AS (2020) A C-terminal peptide from type I interferon protects the retina in a mouse model of autoimmune uveitis. PLoS ONE 15(2): e0227524.

show abstract

“…Recombinant type I interferons (IFN and IFN), have been approved for the treatment of a number of malignancies, viral infections and multiple sclerosis (43). In addition, IFN has been used in Europe to treat various forms of uveitis (27,44). However, their use in the clinic is associated with severe toxicity, including lymphopenia, depression and weight loss.…”

Section: Discussionmentioning

confidence: 99%

“…This has been exploited to develop treatments for multiple sclerosis (24), psoriasis (25), and coeliac diseases (26). Several studies have reported the success of use of IFN in a number of ocular disorders, including uveitis (27)(28)(29). Type I interferon (IFN or IFN) are commonly used to treat relapsing multiple sclerosis (MS) (24).…”

Section: Introductionmentioning

confidence: 99%

A Cell Penetrating Peptide from Type I Interferon Protects the Retina in a Mouse Model of Autoimmune Uveitis

Ahmed

et al. 2019

Preprint

View full text Add to dashboard Cite

Experimental autoimmune uveitis (EAU) in rodents recapitulates many features of the disease in humans and has served as a useful tool for the development of therapeutics. A peptide from C-terminus of interferon 1, conjugated to palmitoyl-lysine for cell penetration, denoted as IFN-C, was tested for its anti-inflammatory properties in ARPE-19 cells, followed by testing in a mouse model of EAU. Treatment with IFN-C and evaluation by RT-qPCR showed the induction of anti-inflammatory cytokines and chemokine. Inflammatory markers induced by treatment with TNF were suppressed when IFN-C was simultaneously present. TNF- mediated induction of NF-kB and signaling by IL-17A were attenuated by IFN-C.Differentiated ARPE-19 cells were treated with TNF in the presence or absence IFN-C and analyzed by immmunhistochemistry. IFN-C protected against the disruption integrity of tight junction proteins. Similarly, loss of transepithelial resistance caused by TNF was prevented by IFN-C. B10.RIII mice were immunized with a peptide from interphotoreceptor binding protein (IRBP) and treated by gavage with IFN-C. Development of uveitis was monitored by histology, fundoscopy, SD-OCT, and ERG. Treatment with IFN-C prevented uveitis in mice immunized with the IRBP peptide. Splenocytes isolated from mice with ongoing EAU exhibited antigenspecific T cell proliferation that was inhibited in the presence of IFN-C. IFN-C peptide exhibits anti-inflammatory properties and protects mice against damage to retinal structure and function suggesting that it has therapeutic potential for the treatment of autoimmune uveitis.

show abstract

Interferon Alpha 2a and 2b in Ophthalmology: A Review

Cited by 44 publications

References 70 publications

Ocular Manifestations in Patients with Philadelphia-Negative Myeloproliferative Neoplasms

Ocular Manifestations in Patients with Philadelphia-Negative Myeloproliferative Neoplasms

A C-terminal peptide from type I interferon protects the retina in a mouse model of autoimmune uveitis

A Cell Penetrating Peptide from Type I Interferon Protects the Retina in a Mouse Model of Autoimmune Uveitis

Contact Info

Product

Resources

About